Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Express Scripts
Boehringer Ingelheim
McKesson
Moodys

Last Updated: June 28, 2022

CLINICAL TRIALS PROFILE FOR OSELTAMIVIR PHOSPHATE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Oseltamivir Phosphate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00416962 ↗ Safety and Pharmacokinetic Effects of Oseltamivir Alone or in Combination With Amantadine Completed Hoffmann-La Roche Phase 1 2006-08-01 This study is designed to assess the safety and pharmacokinetic effects of oseltamivir administration alone or in combination with amantadine in healthy volunteers.
NCT00416962 ↗ Safety and Pharmacokinetic Effects of Oseltamivir Alone or in Combination With Amantadine Completed Novartis Phase 1 2006-08-01 This study is designed to assess the safety and pharmacokinetic effects of oseltamivir administration alone or in combination with amantadine in healthy volunteers.
NCT00453999 ↗ Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza Completed BioCryst Pharmaceuticals Phase 2 2007-07-01 This study has been designed as a randomized, double-blind, controlled, study to evaluate the efficacy and safety of two once daily intravenous peramivir regimens (200 mg and 400 mg) versus oral oseltamivir phosphate (75 mg twice daily) in hospitalized subjects with acute serious or potentially life threatening influenza. Study treatments will be provided for up to 5 consecutive days.
NCT00803595 ↗ A Multinational Phase III Study of CS-8958 (MARVEL) Completed Daiichi Sankyo Co., Ltd. Phase 3 2008-11-01 The primary objective of this study is to confirm the efficacy of CS-8958 administered as a single inhaled low dose or single inhaled high dose by showing non-inferiority to oseltamivir phosphate using the time to alleviation of influenza illness. For safety evaluation, between-group comparisons will be made with regard to incidence of adverse events and other safety measures. In a secondary objective, the optimum dosage of CS-8958 for this indication will be evaluated based on the efficacy and safety of single inhaled low or high dose.
NCT00979251 ↗ Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects Completed Adamas Pharmaceuticals, Inc. Phase 2 2009-09-01 This Phase 2, open label, randomized study will investigate the virologic benefit, clinical efficacy, safety, and tolerability of amantadine and ribavirin with oseltamivir (TCAD) versus oseltamivir monotherapy for the treatment of all strains of influenza A in immunocompromised adult and pediatric subjects.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Oseltamivir Phosphate

Condition Name

Condition Name for Oseltamivir Phosphate
Intervention Trials
Influenza 9
Bioequivalence 3
Healthy 1
Virus Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Oseltamivir Phosphate
Intervention Trials
Influenza, Human 12
COVID-19 2
Metabolic Diseases 1
Obesity 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Oseltamivir Phosphate

Trials by Country

Trials by Country for Oseltamivir Phosphate
Location Trials
United States 49
Australia 13
South Africa 12
Canada 9
China 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Oseltamivir Phosphate
Location Trials
New Jersey 4
Florida 3
Texas 3
New York 3
Louisiana 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Oseltamivir Phosphate

Clinical Trial Phase

Clinical Trial Phase for Oseltamivir Phosphate
Clinical Trial Phase Trials
Phase 4 5
Phase 3 4
Phase 2 5
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Oseltamivir Phosphate
Clinical Trial Phase Trials
Completed 12
Recruiting 4
Unknown status 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Oseltamivir Phosphate

Sponsor Name

Sponsor Name for Oseltamivir Phosphate
Sponsor Trials
Hoffmann-La Roche 4
Jiangxi Qingfeng Pharmaceutical Co. Ltd. 2
Laboratorios Andromaco S.A. 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Oseltamivir Phosphate
Sponsor Trials
Other 39
Industry 17
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Dow
Express Scripts
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.